Cargando…

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis

Limited information exists regarding the optimal dose of posaconazole delayed-release tablet for the treatment of invasive mold infection. Here, we report the case of a previously healthy 44-year-old Thai man who developed coexisting invasive pulmonary aspergillosis and mucormycosis following a car...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leelawattanachai, Pannee, Montakantikul, Preecha, Nosoongnoen, Wichit, Chayakulkeeree, Methee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497849/ https://www.ncbi.nlm.nih.gov/pubmed/31114213 http://dx.doi.org/10.2147/TCRM.S203625

Ejemplares similares

Evaluation of Intravenous Fosfomycin Disodium Dosing Regimens in Critically Ill Patients for Treatment of Carbapenem-Resistant Enterobacterales Infections Using Monte Carlo Simulation
por: Leelawattanachai, Pannee, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
por: Wiederhold, Nathan P
Publicado: (2015)

Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases
por: Khan-asa, Buddharat, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics studies of a loading dose of cisatracurium in critically ill patients with respiratory failure
por: Panusitthikorn, Panadda, et al.
Publicado: (2022)

The use of posaconazole delayed-release tablets in the successful treatment of suspected mucormycosis in a bottlenose dolphin (Tursiops truncatus) calf
por: Marques, Gonçalo N., et al.
Publicado: (2021)

Chronic Pulmonary Aspergillosis Following Nontuberculous Mycobacterial Infections: An Emerging Disease
por: Phoompoung, Pakpoom, et al.
Publicado: (2020)

976. Population Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analysis of Intravenous Fosfomycin for Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
por: Belling, Morgan, et al.
Publicado: (2017)

2546. Administration of Crushed Posaconazole Delayed Release Tablets Failed to Achieve Therapeutic Levels
por: Kane, Nicholas, et al.
Publicado: (2023)

A case report of intravenous posaconazole in hepatic and renal impairment patient with invasive Aspergillus terreus infection: safety and role of therapeutic drug monitoring
por: Dilokpattanamongkol, Pitchaya, et al.
Publicado: (2017)

Characteristics and Outcomes of Patients with Invasive Pulmonary Aspergillosis and Respiratory Tract Aspergillus Colonization from a Tertiary University Hospital in Thailand
por: Soontrapa, Pannathat, et al.
Publicado: (2022)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

Clinical pharmacokinetics and dose recommendations for posaconazole gastroresistant tablets in children with cystic fibrosis
por: Bentley, Siân, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic (PK/PD) Simulation for Dosage Optimization of Colistin Against Carbapenem-Resistant Klebsiella pneumoniae and Carbapenem-Resistant Escherichia coli
por: Jitaree, Kamonchanok, et al.
Publicado: (2019)

Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs
por: Corrigan, V.K., et al.
Publicado: (2016)

Management of mucormycosis coexisting with aspergillosis in pediatric age group – a case report
por: Gopal, Ashish, et al.
Publicado: (2023)

Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis
por: Maertens, Johan A., et al.
Publicado: (2023)

Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies
por: Leclerc, Elisabeth, et al.
Publicado: (2018)

Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Tallman, Gregory B, et al.
Publicado: (2017)

Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Furuno, Jon P., et al.
Publicado: (2018)

Successful treatment of pulmonary mucormycosis caused by Rhizopus microsporus with posaconazole
por: Yuan, F., et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
por: Kukulka, Michael, et al.
Publicado: (2016)

Pharmacokinetics and Pharmacodynamics of Gliclazide from Immediate and Modified Release Formulation Tablets in Rats
por: Resztak, M, et al.
Publicado: (2014)

Successful treatment of cutaneous mucormycosis disseminated from pulmonary mucormycosis with liposomal amphotericin B and posaconazole
por: Ding, Xiao-Lan, et al.
Publicado: (2020)

1423. Plasma and Intrapulmonary Pharmacokinetics of Sitafloxacin in Thai Critically Ill Patients With Pneumonia
por: Paiboonvong, Taniya, et al.
Publicado: (2018)

Advances against Aspergillosis and Mucormycosis
por: Stevens, David A.
Publicado: (2020)

Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature
por: Sandherr, M, et al.
Publicado: (2011)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
por: Cornely, Oliver A., et al.
Publicado: (2016)

941. Isavuconazole Prophylaxis Against Invasive Fungal Infection: A Pooled Analysis with a Comparison of Posaconazole Delayed-release Tablet Prophylaxis
por: Lee, Chaeryoung, et al.
Publicado: (2021)

Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
por: Kang, Seung Hun, et al.
Publicado: (2015)

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018)

A Review of Population Pharmacokinetic Models of Posaconazole
por: Ding, Qin, et al.
Publicado: (2022)

S1.4b Challenges in diagnosing and management of invasive fungal infections during the pandemic
por: Chayakulkeeree, Methee
Publicado: (2022)

Interaction between posaconazole and flucloxacillin in a lung transplant patient: decrease in plasma exposure of posaconazole and possible undertreatment of invasive aspergillosis: case report
por: Verfaillie, Saartje, et al.
Publicado: (2022)

High‐dose posaconazole for azole‐resistant aspergillosis and other difficult‐to‐treat mould infections
por: Schauwvlieghe, Alexander F. A. D., et al.
Publicado: (2019)

Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children
por: Boonsathorn, Sophida, et al.
Publicado: (2018)

External evaluation of published population pharmacokinetic models of posaconazole
por: Huang, Shuqi, et al.
Publicado: (2022)

Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis
por: Wu, Hailan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bhssec6kme9euse4ftcojnkl1i